All In Biotech

Drug Trial Radar · NCT06442423

Open-Label Psilocybin Study in Transdiagnostic Population

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 17, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Usona Institute; Brain & Behavior Research Foundation
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. A DSM-5 diagnosis is not required (nor is it an exclusion). The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions. The investigators will employ an open-label study where participants will be given one dose of oral psilocybin 25mg. The investigators will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months.

Conditions

  • Transdiagnostic
  • Depression - Major Depressive Disorder
  • Anxiety
  • PTSD Symptoms
  • PTSD
  • Substance Use
  • Substance Use Disorder (SUD)
  • OCD

Interventions

  • PsilocybinDrug

    Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 6 weeks
  2. Adverse Events LogTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Connecticut Mental Health Center - Yale School of Medicine

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.